SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit

Reference: KPTX02
Product nameSARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit
Delivery conditionBlue ice (+4°)
Storage conditionStable for 6 months from the date of manufacture if Capture Plate, Controls and HRP conjugated ACE2 are kept at -20°C. The remaining reagents can be stored at 4°C.
Size1 Kit, 96 tests
NoteFor research use only.
Label or DyeHorseradish Peroxidase (HRP)
IsotypeAny isotype
Sample typePurified Antibody, serum
Expected control ResultsPositive Control OD450 nm < 0.3
Negative Control OD450nm > 0.9
Assay typeQuantitative
Detection methodColorimetric

General information on SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit

The surrogate Virus Neutralization Test (sVNT) was designed in the versatile ELISA format allowing the quick and parallel screening of multiple purified antibodies and serum samples with potent neutralizing activity. With no species, isotype, or antibody format restriction, it is now possible to perform a preliminary assessment of an antibody or a sample neutralizing potential in less than 2 hours and without needing to use live mammalian cells or native viral particles.
The test works according to the principle of competitive binding between a purified antibody and HRP-labeled human ACE2 (angiotensin-converting enzyme 2), which is the natural ligand of the receptor-binding domain (RBD) in the COVID-19 pathology. For accurate detection, the test kit comprises the following reagents:
• Horseradish peroxidase (HRP) labeled ACE2
• Capture plate coated with unlabeled RBD
• The HRP substrate, TMB (3,3′,5,5′-Tetramethylbenzidine)
• Positive and negative controls
The test works according to the principle of competitive inhibition. In the presence of SARS-CoV-2 neutralizing antibodies (NAbs), the interaction between the RBD and the ACE2 is hampered leading to low or no detectable signal. On the contrary, in the presence of unspecific antibodies (Abs) the formation of the HRT-ACE2-RBD complex takes place leading to an intense signal.
The test kit is for research use only and it can serve as a tool for immune surveillance of large populations or regions. The test also serves as a preliminary assessment of SARS-CoV-2 neutralization potential for candidate antibodies obtained either by in vivo antibody discovery technologies (e.g. hybridoma) or in vitro methodologies such as phage display.
The advantage of using the sVNT kit lies on the possibility of shortening the development times of neutralizing antibodies by reducing the number of promising molecules that need to be validated in traditional viral neutralization tests which are time-consuming such as the pseudo-virus neutralization tests (pVNT) and require access to facilities with biosafety level 3 (BSL3) such as the plaque reduction neutralization test (PRNT).


  • Tutukina, M. et al. IgG Antibodies Develop to Spike but Not to the Nucleocapsid Viral Protein in Many Asymptomatic and Light COVID-19 Cases. Viruses. 2021; 13(10):1945. doi: 10.3390/v13101945
  • Kaznadzey A., Tutukina M., Bessonova T., Kireeva M., Mazo I. BNT162b2, mRNA-1273, and Sputnik V vaccines induce comparable immune responses on a par with severe course of COVID-19. medRxiv. 2022.02.03.21265607. doi: 10.1101/2022.02.03.21265607
  • Per-Olof Syren, David Hueting, Karen Schriever et al. Design, structure and plasma binding of ancestral β-CoV scaffold antigens, 16 September 2022, PREPRINT (Version 1) available at Research Square []
  • Moreno, A.; Lelli, D.; Trogu, T.; Lavazza, A.; Barbieri, I.; Boniotti, M.; Pezzoni, G.; Salogni, C.; Giovannini, S.; Alborali, G.; Bellini, S.; Boldini, M.; Farioli, M.; Ruocco, L.; Bessi, O.; Maroni Ponti, A.; Di Bartolo, I.; De Sabato, L.; Vaccari, G.; Belli, G.; Margutti, A.; Giorgi, M. SARS-CoV-2 in a Mink Farm in Italy: Case Description, Molecular and Serological Diagnosis by Comparing Different Tests. Viruses 2022, 14, 1738.
  • Cosan, F., Demirel, O.U., Yalcin, D. et al. Comparison of anti-spike IgG, anti-spike IgA levels and neutralizing antibody activity induced by CoronaVac and BNT162b2 vaccines in patients with inflammatory rheumatic diseases receiving immunosuppressive therapy. BMC Rheumatol 7, 20 (2023).
  • Streif, S., Neckermann, P., Spitzenberg, C. et al. Liposome-based high-throughput and point-of-care assays toward the quick, simple, and sensitive detection of neutralizing antibodies against SARS-CoV-2 in patient sera. Anal Bioanal Chem 415, 1421–1435 (2023).


There are no reviews yet.


Be the first to review “SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit”

Your email address will not be published. Required fields are marked *

Related products

RBD Domain

RBD Domain

PX-COV-P046 250€
ACE2 protein &#8211; Soluble ectodomain of human ACE-2 (aa 1-740)

ACE2 protein – Soluble ectodomain of human ACE-2 (aa 1-740)

PX-COV-P048 230€

Contact us

Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.

    Cart (0 Items)

    Your cart is currently empty.

    View Products